肺动脉高压的病理学与病理生物学:当前见解与未来方向
本文为第七届世界肺动脉高压研讨会会议记录,聚焦肺动脉高压病理学与病理生理学最新进展。文中讨论细胞与分子机制在肺动脉重塑中的作用,涵盖肺动脉高压、左心疾病相关、慢性肺病与缺氧相关及慢性血栓栓塞性肺动脉高压,并探讨组学技术如何加速基础机制理解及改善患者管理、药物研发与研究支持。
要点
- 不同亚型肺动脉高压的细胞与分子重塑机制已有重要进展。
- 各型肺动脉高压生存率仍不理想,亟需将科学知识转化为临床干预。
- 组学等技术有望加速阐明肺动脉重塑的启动与进展机制。
核心结论
- 肺动脉高压病理生物学取得重要进展,但各型生存率仍不理想,需更有效转化科学知识为医疗干预。
研究设计与样本
- 第七届世界肺动脉高压研讨会会议记录,聚焦病理学与病理生理学领域最新进展并讨论其在不同亚型中的相关性。
主要发现
- 对肺动脉高压、左心疾病相关、慢性肺病与缺氧相关及慢性血栓栓塞性肺动脉高压的细胞与分子重塑机制理解已有重大进展。
- 最新组学及其他技术进步有助于更好、更快速地理解肺动脉重塑启动与进展的多种基础机制。
临床怎么用
- 讨论旨在改善患者照护、优化药物开发并为推进该领域研究提供必要支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, major advances have been made in the understanding of the cellular and molecular mechanisms driving pulmonary vascular remodelling in various forms of pulmonary hypertension, including pulmonary arterial hypertension, pulmonary hypertension associated with left heart disease, pulmonary hypertension associated with chronic lung disease and hypoxia, and chronic thromboembolic pulmonary hypertension. However, the survival rates for these different forms of pulmonary hypertension remain unsatisfactory, underscoring the crucial need to more effectively translate innovative scientific knowledge into healthcare interventions. In these proceedings of the 7th World Symposium on Pulmonary Hypertension, we delve into recent developments in the field of pathology and pathophysiology, prioritising them while questioning their relevance to different subsets of pulmonary hypertension. In addition, we explore how the latest omics and other technological advances can help us better and more rapidly understand the myriad basic mechanisms contributing to the initiation and progression of pulmonary vascular remodelling. Finally, we discuss strategies aimed at improving patient care, optimising drug development, and providing essential support to advance research in this field.
引用
- Guignabert C, Aman J, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. Eur Respir J. 2024. PMID: 39209474. doi:10.1183/13993003.01095-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。